Modulation of drug-drug interactions of vadadustat
Номер патента: EP4301352A1
Опубликовано: 10-01-2024
Автор(ы): Ajit CHAVAN, Steven Burke
Принадлежит: Akebia Therapeutics Inc
Опубликовано: 10-01-2024
Автор(ы): Ajit CHAVAN, Steven Burke
Принадлежит: Akebia Therapeutics Inc
Реферат: Provided herein are methods for reducing, minimizing, or controlling drug-drug interactions resulting from administration of a drug (e.g., a first drug) that is vadadustat (i.e., {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound 1)) and another (e.g., a second) drug (e.g., a drug comprising a polymeric amine that binds phosphate (e.g., sevelamer hydrochloride or sevelamer carbonate); or inhibitors and/or substrates of certain proteins, receptors, and/or transporters (e.g., probenecid, cyclosporine, rifampin, digoxin, or adefovir))
Modulation of drug-drug interactions of vadadustat
Номер патента: AU2022229275A1. Автор: Steven Burke,Ajit CHAVAN. Владелец: Akebia Therapeutics Inc. Дата публикации: 2023-10-12.